Oestrogen attenuates tumour progression in hepatocellular carcinoma

Authors

  • Hanwen Xu,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Yinna Wei,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Yu Zhang,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Yichen Xu,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
  • Feng Li,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
  • Jing Liu,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
  • Wei Zhang,

    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    Search for more papers by this author
  • Xiaodong Han,

    1. Reproduction and Immunology Laboratory, Medical School, Nanjing University, Nanjing, China
    Search for more papers by this author
  • Renxiang Tan,

    1. State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Search for more papers by this author
  • Pingping Shen

    Corresponding author
    1. State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing, China
    • State Key Laboratory of Pharmaceutical Biotechnology and Model Animal Research Center, Nanjing University, Nanjing 210093, China.
    Search for more papers by this author

  • No conflicts of interest were declared.

Abstract

The precise mechanisms underlying gender disparity in hepatocellular carcinoma (HCC) progression and prognosis are not understood. We demonstrate that oestrogen attenuates HCC progression in vitro and in vivo, and this may contribute to the gender differences in HCC behaviour. To investigate the role of oestrogen in HCC progression, we developed an orthotopic homograft tumour model by liver implantation of H22 cells. In combination with male castration, female ovariectomy, and oestrogen treatment, we tested the hypothesis that oestrogen contributes to gender disparity in this model. Pathological analyses were performed to examine the changes in biological behaviour of liver cancer cells, and two cell lines were used to investigate possible molecular mechanisms of the suppressive effect of oestrogen. Our data showed that oestrogen modulates HCC malignancy in vivo by reducing tumour cell invasion, arresting cell cycle progression, and promoting apoptosis, characterized by decreased expression of MMP-2, MMP-9, PCNA, cyclin A, cyclin D1, and Bcl-2, and increased expression in cleaved caspase 3. Through in vitro assays, we further confirmed the changes in expression levels of these related proteins, gained insights into the molecular cascades of oestrogen-induced HCC suppression, and indicated the oestrogen receptor α-mediated inhibition of NF-κB binding activity as a pivotal event in this process. This study represents a novel description of the mechanisms regarding the suppressive effects of oestrogen on HCC, adding a new understanding to the gender disparity in HCC progression. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Ancillary